| pubmed-article:19325231 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19325231 | lifeskim:mentions | umls-concept:C0006684 | lld:lifeskim |
| pubmed-article:19325231 | lifeskim:mentions | umls-concept:C0086907 | lld:lifeskim |
| pubmed-article:19325231 | lifeskim:mentions | umls-concept:C0288263 | lld:lifeskim |
| pubmed-article:19325231 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19325231 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19325231 | pubmed:dateCreated | 2009-8-17 | lld:pubmed |
| pubmed-article:19325231 | pubmed:abstractText | The L/N-type calcium channel blocker (CCB) cilnidipine has been demonstrated to suppress sympathetic nerve activity. In the present study, we investigated the effects of cilnidipine on the renin-angiotensin-aldosterone system (RAAS) in SHR/Izm rats to confirm differences from the effects of L-type CCB. | lld:pubmed |
| pubmed-article:19325231 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19325231 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19325231 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19325231 | pubmed:issn | 1421-9670 | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:KoganeiHajime... | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:NittaKosakuK | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:OgawaTetsuyaT | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:KondaTomoyuki... | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:EnomotoAzusaA | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:AritomiShizuk... | lld:pubmed |
| pubmed-article:19325231 | pubmed:author | pubmed-author:NiinumaKazumi... | lld:pubmed |
| pubmed-article:19325231 | pubmed:copyrightInfo | Copyright 2009 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:19325231 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19325231 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:19325231 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19325231 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19325231 | pubmed:pagination | 155-61 | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:meshHeading | pubmed-meshheading:19325231... | lld:pubmed |
| pubmed-article:19325231 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19325231 | pubmed:articleTitle | Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. | lld:pubmed |
| pubmed-article:19325231 | pubmed:affiliation | Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki, Kanagawa, Japan. tomoyuki_konda@ajinomoto.com | lld:pubmed |
| pubmed-article:19325231 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19325231 | lld:pubmed |
